Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Crucell Terug naar discussie overzicht

Shantha

259 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste | Omlaag ↓
  1. [verwijderd] 15 maart 2010 10:33
    WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
    OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA

    triangle.bizjournals.com/triangle/sto...

    Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.

    ivet
  2. [verwijderd] 15 maart 2010 10:38
    quote:

    invoorentegenspoed schreef:

    WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
    OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA

    triangle.bizjournals.com/triangle/sto...

    Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.

    ivet
    Bron?

    Link slaat op Viehbacher.

    Dirk
  3. [verwijderd] 15 maart 2010 10:39
    quote:

    invoorentegenspoed schreef:

    WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
    OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA

    triangle.bizjournals.com/triangle/sto...

    Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.

    ivet
    hahahahahhahahhahahhahhhahhahhahahahhhahah!!!!!!

    yayayayayayayay!!!!

    ROTFLMAO
  4. [verwijderd] 15 maart 2010 10:45
    quote:

    Dirk R. Wijnen schreef:

    [quote=invoorentegenspoed]
    WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
    OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA

    triangle.bizjournals.com/triangle/sto...

    Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.

    ivet
    [/quote]

    Sorry, moet zijn: www.who.int/immunization_standards/va...

    Bron?

    Link slaat op Viehbacher.

    Dirk
    www.who.int/immunization_standards/va...
  5. [verwijderd] 15 maart 2010 10:48
    waarschijnlijk verkeerde toets bij copy/paste, waardoor voorlaatste link per abuis werd vermeld, dus nog maar een keertje ter verduidelijking:

    www.who.int/immunization_standards/va...

    misschien is er een moderator in de zaal die de link in de eerste posting wil vervangen voor deze hierboven?

    bvd ivet
  6. [verwijderd] 15 maart 2010 10:48
    Joint WHO-UNICEF Statement 2
    12 March 2010
    WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
    OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA
    As of 12 March 2010 the World Health Organization (WHO) recommends to stop procurement and to suspend use of all lots of the Shan5 vaccine supplied to countries pending ongoing investigations.
    Countries are advised to put any remaining vaccine in quarantine until further notice.
    If it is confirmed that the country has received shipments of any lot of Shan5 vaccine, the vaccine should not be used, but kept under recommended storage conditions, clearly marked ‘QUARANTINED; NOT TO BE USED OR DISTRIBUTED’ until further direction is provided by WHO.
    WHO recommends that countries continue vaccination using pentavalent vaccine from an alternative manufacturer or an alternate DTP-containing vaccine until further notice. Countries may contact WHO and UNICEF country offices for assistance to fill shortfalls in vaccine supply as a result of the temporary suspension
  7. forum rang 4 aossa 15 maart 2010 10:55
    Zoals al meermaals in de praktijk bewezen 'haast en spoed zijn zelden goed'...
  8. harrysnel 15 maart 2010 11:04
    Juiste keuze mbt positionering van Crucell als betrouwbare leverancier wordt hiermee mooi onderstreept. Ook op lange termijn een gunstige ontwikkeling. Bij Crucell viel al langer een EZDG mbt Shanta en produktlevering te beluisteren..
  9. forum rang 4 aossa 15 maart 2010 11:09
    www.who.int/immunization_standards/va...

    (vervolg)
    History of temporary suspension
    • On 19 February 2010, WHO recommended the temporary suspension of the distribution and use of specific lots of Shan5 vaccine due to the presence of a white sediment which sticks to the glass of the vaccine vial that is difficult or impossible to re-suspend with vigorous shaking (flocculation).This action was taken as a precautionary measure pending investigation of vaccine quality complaints from Colombia, Comoros and Nepal.
    • Countries where the affected lots were distributed were contacted by WHO and requested to check all the available lots of the Shan5 vaccine. Some countries reported that additional lots that were not included in the temporary suspension also showed a similar problem.
    • For instance, the Democratic Republic of the Congo reported that 15 out of 24 lots checked showed the presence of the above-mentioned white sediment that could not be re-suspended. In addition, Médecins sans Frontières reported to WHO a similar complaint concerning a lot number that was not included in the lots initially suspended on 19 February; this issue was reported directly to the manufacturer in 2009.
    • Distribution information indicates that the Shan5 vaccine had been supplied through UN agencies or by direct procurement to Central African Republic, Chad, Colombia,
    1
    Comoros, Democratic Republic of the Congo, Lao People's Democratic Republic, Mauritania, Mozambique, Nepal, Nicaragua, Pakistan, Republic of Congo and Tanzania.
    Supply of alternative vaccine
    • UNICEF Supply Division is working with the country offices to ensure prompt supply of alternative product to enable resumption of vaccination. Countries are encouraged to ensure that UNICEF Country Offices are included on all aspects of dealing with this issue and kept closely informed.
    UNICEF country offices will provide details of quantities and cold storage requirements of the first possible shipment of new vaccines. Countries need to review and confirm they have sufficient cold storage capacity and to inform whether there are any other impediments in accepting the delivery, such as registration requirements, etc..
    • As the suspension is a precautionary measure pending the outcome of an investigation, and as long as the supplier had not recalled the vaccine, any claims processing is pending the outcome and conclusion of the investigation. WHO will keep UNICEF and the countries informed of the timeline for this.
    • In this initial phase, the focus is on ensuring new vaccine deliveries to countries so vaccination can be resumed. Beyond the immediate supply, UNICEF will work with countries and partners to assess the funding and vaccine requirement for the rest of 2010 with a view to identifying solutions.
    Shan5 vaccine quality and safety
    • None of the information available to date suggests a vaccine safety problem with the Shan5 vaccine.
    • No adverse events following immunization with Shan5 have been reported to WHO.
    • No other vaccine quality complaints besides the flocculation described above have been reported to WHO.
    • A vaccine quality investigation by the manufacturer and WHO is ongoing. The available information to date is insufficient to make conclusions about the potential causes of the flocculation as reported.
    • The manufacturer's Quality Assurance Department has performed investigations that include: review of the batch records for deviations; changes in the manufacturing process including raw materials; review of the cold chain during transportation of the vaccines (temperature monitoring devices); and retesting of the retention samples. Additional Research and Development Department experiments are being performed by the manufacturer.
    • WHO is conducting a vaccine quality review, including independent testing by WHO- contracted laboratories. This will include scanning electron microscopy (SEM) and X-ray elemental analysis of particles in SEM — procedures that are not routinely used in the quality control of the vaccines.
    Further advice will be issued by WHO/UNICEF pending the outcome of the investigation performed by the manufacturer and WHO.
    Shan5 vaccine composition and WHO prequalification:
    Shan5 is a combined, pentavalent vaccine containing diphtheria, tetanus, whole cell pertussis recombinant DNA, hepatitis B, and Hib components. The vaccine is absorbed onto aluminium salts as an adjuvant and preserved with thiomersal.
    2
    Shan5 is a WHO prequalified vaccine supplied through UN agencies. Between January 2008 and February 2010 approximately 23 945 082 doses of this vaccine have been supplied through UNICEF and the Revolving Fund of the Pan-American Health Organization. The vaccine is also procured directly for use by public immunization services in a number of countries.
    Shan5 vaccine currently remains on the WHO list of prequalified vaccines supplied through UN agencies. The WHO web page on prequalification indicates that the vaccine is temporarily suspended pending the outcome of the investigation.
    __________________
    This WHO-UNICEF joint statement supplements a previous communication by WHO to UNICEF, WHO Regional Advisers for Immunization and Vaccine Quality, and the Global Alliance for Vaccines and Immunisation advising of the temporary suspension of specific lots of Shan5 vaccine produced by Shantha Biotechnics India, and actions to be taken.
    3
  10. forum rang 4 aossa 15 maart 2010 11:12
    Maw EXTRA druk op Shantha vanuit WHO... (mogelijk omwille van een prul)

    (Wat zegt de project-controller daarover ? Aja, het gaat ze waarschijnlijk VEEL EXTRA geld kosten)
  11. [verwijderd] 15 maart 2010 11:17
    Merkwaardig dat de koers hier nog pas "matig" op heeft gereageerd. Dit bericht lijkt mij zeer gunstig voor zowel de volumes als de prijzen van de aanstaande QV-contracten.

    Ik heb mijn handelsvoorraad in ieder geval even stevig aangevuld.
  12. maxen 15 maart 2010 11:19
    quote:

    invoorentegenspoed schreef:

    www.who.int/immunization_standards/va...
    History of temporary suspension
    • On 19 February 2010, WHO recommended the temporary suspension of the distribution and use of specific lots of Shan5 vaccine due to the presence of a white sediment which sticks to the glass of the vaccine vial that is difficult or impossible to re-suspend with vigorous shaking (flocculation).This action was taken as a precautionary measure pending investigation of vaccine quality complaints from Colombia, Comoros and Nepal.
    • Countries where the affected lots were distributed were contacted by WHO and requested to check all the available lots of the Shan5 vaccine. Some countries reported that additional lots that were not included in the temporary suspension also showed a similar problem.
    • For instance, the Democratic Republic of the Congo reported that 15 out of 24 lots checked showed the presence of the above-mentioned white sediment that could not be re-suspended. In addition, Médecins sans Frontières reported to WHO a similar complaint concerning a lot number that was not included in the lots initially suspended on 19 February; this issue was reported directly to the manufacturer in 2009.
    • Distribution information indicates that the Shan5 vaccine had been supplied through UN agencies or by direct procurement to Central African Republic, Chad, Colombia, Comoros, Democratic Republic of the Congo, Lao People's Democratic Republic, Mauritania, Mozambique, Nepal, Nicaragua, Pakistan, Republic of Congo and Tanzania.

    Kortom:
    Er is een wittige neerslag onstaan in de buisjes Shan5, die niet/moeilijk meer op te lossen is door te schudden.

    Waarschijnlijk is/zijn 1 of meer van de componenten van het vaccin neergeslagen. Uiteraard kan een vaccin met neerslag niet meer worden ingespoten. De know-how die het in Quivaxem voor het eerst mogelijk maakte om de vijf pentavalent componenten allemaal op te lossen en opgelost te HOUDEN, blijkt behoorlijk ingewikkeld. Het gekke is daarbij dat Shanta die know-how van Berna heeft ,wat royalties voor Crucell betekent: zie bv. pagina 30 van:

    hugin.info/132631/R/1359009/331102.pdf

    Tender period 2010-2012: new Indian competition from Shantha (royalties for Crucell), Panacea

    Crucell has stake in Shantha/Sanofi Pasteur pentavalent vaccine.

    Dus het zit hem bij Shanta dan wellicht niet in de know-how, maar in de juiste uitvoering daarvan?

    In ieder geval hele slechte zaak voor Shanta.
    Goed voor Crucell als vervangende leverancier, maar slecht voor 't imago voor pentavalent vaccins als geheel, dus ook 'n beetje voor Crucell.
  13. [verwijderd] 15 maart 2010 11:22
    quote:

    xynix schreef:

    Merkwaardig dat de koers hier nog pas "matig" op heeft gereageerd. Dit bericht lijkt mij zeer gunstig voor zowel de volumes als de prijzen van de aanstaande QV-contracten.

    Ik heb mijn handelsvoorraad in ieder geval even stevig aangevuld.
    hou er rekening mee dat koers en fundamenten niet één op één bewegen...

    CRXL is m.i. een prima belegging, maar wat het bedrijf presteert en wat de koers 'presteert', loopt nog wel eens uiteen.

    mvg ivet
  14. maxen 15 maart 2010 11:24
    quote:

    ronbanged2 schreef:

    Can anyone confirm...this is big if it is true.

    ...the stealing of market share outside of India by Panacea and Shantha...
    Kom er maar in met de schattingen wat dit voor 't marktaandeel van Crucell betekent.
  15. z0n0p 15 maart 2010 11:24
    Het is in geval van Crucell al 145 miljoen keer goed gegaan. Dus vooral shame on Shanta.
  16. forum rang 9 josti5 15 maart 2010 11:37
    quote:

    maxen schreef:

    [quote=ronbanged2]
    Can anyone confirm...this is big if it is true.

    ...the stealing of market share outside of India by Panacea and Shantha...
    [/quote]
    Kom er maar in met de schattingen wat dit voor 't marktaandeel van Crucell betekent.
    Nou, geef mij maar liever een PB van Crucell over extra verkopen...

    Kom op, Oya: doe je best en ga er intern voor!
259 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.842
AB InBev 2 5.291
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.524
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.969
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.544
Aedifica 2 832
Aegon 3.257 320.145
AFC Ajax 537 7.018
Affimed NV 2 5.763
ageas 5.843 109.779
Agfa-Gevaert 13 1.864
Ahold 3.536 74.001
Air France - KLM 1.024 34.363
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.610
Allfunds Group 3 1.223
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 339
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.403
AMG 965 126.165
AMS 3 73
Amsterdam Commodities 303 6.524
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.173
Apollo Alternative Assets 1 17
Apple 5 321
Arcadis 251 8.626
Arcelor Mittal 2.024 318.704
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.143
Aroundtown SA 1 179
Arrowhead Research 5 9.284
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.729
ASML 1.762 77.181
ASR Nederland 18 4.128
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.694
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 09 mei

    1. China handelsbalans april
    2. Argenx Q1-cijfers
    3. Hemelvaartsdag, Euronext Amsterdam regulier open
    4. Philips €0,85 ex-dividend
    5. DSM-Firmenich €2,50 ex-dividend
    6. Allfunds €0,0935 ex-dividend
    7. Coca-Cola EP €0,74 ex-dividend
    8. TKH €1,70 ex-dividend
    9. Bank of England - rentebesluit Onveranderd (5,25%)
    10. VS steunaanvragen - wekelijks
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht